Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors

This study has been completed.
Information provided by:
Sunesis Pharmaceuticals Identifier:
First received: August 20, 2007
Last updated: March 5, 2009
Last verified: March 2009
This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.

Condition Intervention Phase
Advanced Solid Tumors
Drug: SNS-314
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1 Open-Label Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors

Further study details as provided by Sunesis Pharmaceuticals:

Primary Outcome Measures:
  • To assess the safety and tolerability of SNS-314 [ Time Frame: 1 Year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: August 2007
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: SNS-314

Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15

Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1

Detailed Description:
Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the blood).

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced solid tumor and that is measurable by a scan

Exclusion Criteria:

  • Uncontrolled or untreated central nervous system metastases
  • Cerebrovascular accident/transient ischemic attack up to 6 months before Cycle 1 Day 1
  • Any of the following cardiac conditions:
  • History of myocardial infarction, acute coronary syndromes up to 12 weeks before Cycle 1 Day 1
  • Class III or IV heart failure up to 6 months before Cycle 1 Day 1
  • Baseline heart rate corrected QT interval (QTc)> 450 msec
  • History of ventricular arrhythmias up to 6 months before Cycle 1 Day 1
  • Use of medications that prolong the QTc interval and are associated with Torsades de Pointe (TdP)
  • Previous cancer treatment up to 21 days before first dose
  • Any investigational therapy up to 28 days before Cycle 1 Day 1
  • Known allergy to cyclodextrins

Please note: There are additional inclusion/exclusion criteria for this study. Please contact the study center for additional information and to determine if all study criteria are met.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00519662

United States, Alabama
University of Alabama, Birmingham
Birmingham, Alabama, United States, 35233
United States, California
Stanford University Medical Center
Stanford, California, United States, 94305
United States, New Mexico
University of New Mexico
Albuquerque, New Mexico, United States, 87131
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Sunesis Pharmaceuticals
Study Director: Glenn Michelson, MD Sunesis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Glenn Michelson, MD, Sunesis Pharmaceuticals, Inc. Identifier: NCT00519662     History of Changes
Other Study ID Numbers: SPO-0011 
Study First Received: August 20, 2007
Last Updated: March 5, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Sunesis Pharmaceuticals:
Advanced processed this record on February 11, 2016